The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Open accessAbstract
Recurrent mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 have been identified in gliomas, acute myeloid leukaemias (AML) and chondrosarcomas, and share a novel enzymatic property of producing 2-hydroxyglutarate (2HG) from α-ketoglutarate. Here we report that 2HG-producing IDH mutants can prevent the histone demethylation that is required for lineage-specific progenitor cells to differentiate into terminally differentiated cells. In tumour samples from glioma patients, IDH mutations were associated with a distinct gene expression profile enriched for genes expressed in neural progenitor cells, and this was associated with increased histone methylation. To test whether the ability of IDH mutants to promote histone methylation contributes to a block in cell differentiation in non-transformed cells, we tested the effect of neomorphic IDH mutants on adipocyte differentiation in vitro. Introduction of either mutant IDH or cell-permeable 2HG was associated with repression of the inducible expression of lineage-specific differentiation genes and a block to differentiation. This correlated with a significant increase in repressive histone methylation marks without observable changes in promoter DNA methylation. Gliomas were found to have elevated levels of similar histone repressive marks. Stable transfection of a 2HG-producing mutant IDH into immortalized astrocytes resulted in progressive accumulation of histone methylation. Of the marks examined, increased H3K9 methylation reproducibly preceded a rise in DNA methylation as cells were passaged in culture. Furthermore, we found that the 2HG-inhibitable H3K9 demethylase KDM4C was induced during adipocyte differentiation, and that RNA-interference suppression of KDM4C was sufficient to block differentiation. Together these data demonstrate that 2HG can inhibit histone demethylation and that inhibition of histone demethylation can be sufficient to block the differentiation of non-transformed cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, 2-HG acts as a competitive inhibitor of α-KG, and its production by mutant IDH1 consumes α-KG (81, 99), leading to reduced TET2 and JmjC activity in tumor cells (79, 80).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [80]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, it is plausible that increased levels of 2-HG may enable a switch to an entirely HIF-independent mechanism.”
From HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells (2021) · cites this paper as [154]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutant IDH protein produces a novel onco-metabolite, 2-hydroxyglutarate (2-HG), that interferes with iron-dependent hydroxylases, including the TET family of 5′-methylcytosine hydroxylases3–7.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [6]
In the citing paper
“In addition to its epigenetic effects, D-2HG inhibits enzymes from the canonical metabolic network (104). Such enzymes include transaminases that produce glutamate for glutathione biosynthesis, rendering IDH-mutant gliomas susceptible to treatments that deplete glutamate and enhance oxidative stress (105).”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [104]
In the citing paper
“The role of R-2-HG as an oncometabolite has been implicated in epigenetic modifications through the inhibition of α-KG-dependent dioxygenases and demethylases”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [118]
In the citing paper
“a neomorphic mutation in IDH1 and/or IDH2 causes a change in enzymatic activity and the accumulation of 2-hydroxyglutarate (2-HG), which inhibits the function of αKG-dependent enzymes such as TET2, resulting in the loss of 5hmC, an increase in DNA methylation and ultimately altered gene expression programmes that drive cancer development66.”
From Targeting cancer vulnerabilities with high-dose vitamin C (2019) · cites this paper as [66]
In the citing paper
“By blocking the enzymatic activity of histone and DNA demethylases, d-2HG can function to lock cells in a hypermethylated state that blocks differentiation and reinforces a malignant and stem cell–like phenotype (30, 172, 173, 174).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [173]
In the citing paper
“In the cancer setting, 2-HG has been shown to influence a number of biological processes, including cell differentiation, DNA methylation, and histone methylation (79–82), leading to its classification as an oncometabolite.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [80]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citationXu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875
The complex language of chromatin regulation during transcription
Berger, S. L. (2007) · Nature · doi:10.1038/nature05915 · Cited by 2,768
Self-citationFigueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Self-citationIdentification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
ATP-citrate lyase links cellular metabolism to histone acetylation
Wellen, K. E., Hatzivassiliou, G., Sachdeva, U. M., Bui, T. V., Cross, J. R., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1164097 · Cited by 2,298
Self-citation
Cited by
Sorted by citations
Items 901–1,000 of 1,001
Non‐canonical metabolic pathways in the malaria parasite detected by isotope‐tracing metabolomics
Cobbold, S. A., Tutor, M. V., Frasse, P., McHugh, E., Karnthaler, M., Creek, D. J., John, A. R. O., Tilley, L. M., Ralph, S. A., & McConville, M. J. (2021) · Molecular Systems Biology · doi:10.15252/msb.202010023 · Cited by 27
IDH1 and IDH2 Mutations in Colorectal Cancers
Huang, J., Tseng, L., Parini, V., Lokhandwala, P. M., Pallavajjala, A., Rodriguez, E. F., Xian, R. R., Chen, L., Gocke, C. D., Eshleman, J. R., et al. (2021) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqab023 · Cited by 27
Garcia-Fabiani, M. B., Haase, S., Comba, A., Carney, S. V., McClellan, B. L., Banerjee, K., Alghamri, M. S., Faisal, S. M., Kadiyala, P., Núñez, F. J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.631037 · Cited by 30
Pappula, A. L., Rasheed, S., Mirzaei, G., Petreaca, R. C., & Bouley, R. A. (2021) · Cancers · doi:10.3390/cancers13174299 · Cited by 27
Oligodendroglioma: A Review of Management and Pathways
Zerdan, M. B., & Assi, H. I. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.722396 · Cited by 30
IDH1/2 mutations in acute myeloid leukemia
Byun, J. M., Yoo, S.-J., Kim, H. J., Ahn, J., Koh, Y., Jang, J. H., & Yoon, S. (2022) · Blood Research · doi:10.5045/br.2021.2021152 · Cited by 33
Cancer stem cells in brain tumors: From origin to clinical implications
Lin, S., Li, K., & Qi, L. (2023) · MedComm · doi:10.1002/mco2.341 · Cited by 27
Functions of idh1 and its mutation in the regulation of developmental hematopoiesis in zebrafish
Shi, X. E., He, A. B.-L., Ma, A. C. H., Guo, Y., Chi, Y., Man, C. H., Zhang, W., Zhang, Y., Wen, Z., Cheng, T., et al. (2015) · Blood · doi:10.1182/blood-2014-09-601187 · Cited by 27
Mitochondria in human pluripotent stem cell apoptosis
TeSlaa, T. A., Setoguchi, K., & Teitell, M. A. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.01.027 · Cited by 25
The mechanisms for minimizing energy expenditure in human locomotion.
Saibene, F. (1990) · PubMed · Cited by 27
Folguera-Blasco, N., Cuyàs, E., Menéndez, J. A., & Alarcón, T. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006052 · Cited by 26
Clinical Grade iPS Cells: Need for Versatile Small Molecules and Optimal Cell Sources
Wu, Y., Pandian, G. N., Ding, Y., Zhang, W., Tanaka, Y., & Sugiyama, H. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.09.016 · Cited by 27
The evolving landscape in the therapy of acute myeloid leukemia
Peloquin, G. L., Chen, Y., & Fathi, A. T. (2013) · Protein & Cell · doi:10.1007/s13238-013-3057-2 · Cited by 26
Single-agent and combination biologics in acute myeloid leukemia
Richard‐Carpentier, G., & Dinardo, C. D. (2019) · Hematology · doi:10.1182/hematology.2019000059 · Cited by 26
Codependency of Metabolism and Epigenetics Drives Cancer Progression: A Review
Masui, K., Harachi, M., Cavenee, W. K., Mischel, P. S., & Shibata, N. (2020) · ACTA HISTOCHEMICA ET CYTOCHEMICA · doi:10.1267/ahc.20002 · Cited by 24
Intermediary metabolism: An intricate network at the crossroads of cell fate and function
Ferreira, L. M. R., Li, A. M., Serafim, T. L., Sobral, M. C. M., Alpoim, M. C., & Urbano, A. M. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165887 · Cited by 27
Targeting Isocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and Diverging Strategies
Waitkus, M. S., & Yan, H. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1827 · Cited by 26
Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL
Simonin, M., Schmidt, A., Bontoux, C., Dourthe, M.-É., Lengliné, É., Andrieu, G. P., Lhermitte, L., Graux, C., Grardel, N., Cayuela, J., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01068-4 · Cited by 26
Characterizing crosstalk in epigenetic signaling to understand disease physiology
Lempiäinen, J. K., & Garcia, B. A. (2023) · Biochemical Journal · doi:10.1042/bcj20220550 · Cited by 29
Critical roles and clinical perspectives of RNA methylation in cancer
Li, G., Yao, Q., Liu, P., Zhang, H., Liu, Y., Li, S., Shi, Y., Li, Z., & Zhu, W. (2024) · MedComm · doi:10.1002/mco2.559 · Cited by 29
Whitehall, V., Dumenil, T. D., McKeone, D., Bond, C., Bettington, M. L., Buttenshaw, R. L., Bowdler, L. M., Montgomery, G. W., Wockner, L. F., & Leggett, B. (2014) · Epigenetics · doi:10.4161/15592294.2014.971624 · Cited by 26
Distinct IDH1/IDH2 mutation profiles in purely insular versus paralimbic WHO Grade II gliomas
Gozé, C., Mansour, L., Rigau, V., & Duffau, H. (2013) · Journal of neurosurgery · doi:10.3171/2012.11.jns121100 · Cited by 26
Chen, J., Yang, J., Sun, X., Wang, Z., Cheng, X., Lu, W., Cai, X., Hu, C., Shen, X., & Cao, P. (2017) · Scientific Reports · doi:10.1038/s41598-017-16427-w · Cited by 29
Polívka, J., Pešta, M., Pitule, P., Hes, O., Holubec, L., Polívka, J., Kubíková, T., & Tonar, Z. (2018) · Oncotarget · doi:10.18632/oncotarget.24536 · Cited by 28
Progress in the problem of relapsed or refractory acute myeloid leukemia
Mims, A. S., & Blum, W. G. (2019) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000490 · Cited by 26
Gregory, B. L., & Cheung, V. G. (2013) · Genome Research · doi:10.1101/gr.156141.113 · Cited by 28
The Role of Somatic Mutations in Acute Myeloid Leukemia PathogenesisPreprint
Kishtagari, A., & Levine, R. L. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034975 · Cited by 26
Self-citationXu, K., Saaoud, F., Shao, Y., Lu, Y., Wu, S., Zhao, H., Chen, K., Vázquez-Padrón, R. I., Jiang, X., Wang, H., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102771 · Cited by 26
Oncometabolite 2-hydroxyglutarate regulates anti-tumor immunity
Cai, M., Zhao, J., Ding, Q., & Wei, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24454 · Cited by 30
Hypoxia-induced epigenetic regulation of breast cancer progression and the tumour microenvironment
Capatina, A. L., Malcolm, J. R., Stenning, J., Moore, R. L., Bridge, K. S., Brackenbury, W. J., & Holding, A. N. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1421629 · Cited by 31
In Vivo Modeling of Malignant Glioma
Kegelman, T. P., Hu, B., Emdad, L., Das, S. K., Sarkar, D., & Fisher, P. B. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-800249-0.00007-x · Cited by 23
Metabolic modulation of chromatin: implications for DNA repair and genomic integrity
Liu, J. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00182 · Cited by 26
Molecularly targeted therapies for acute myeloid leukemia
Stein, E. M. (2015) · Hematology · doi:10.1182/asheducation-2015.1.579 · Cited by 25
Penterling, C., Drexler, G. A., Böhland, C., Stamp, R., Wilke, C., Braselmann, H., Caldwell, R. B., Reindl, J., Girst, S., Greubel, C., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156599 · Cited by 25
Targeting the mitochondria in acute myeloid leukemia
Mendoza, S. E. S., & Rego, E. M. (2017) · Applied cancer research/Applied Cancer Research · doi:10.1186/s41241-017-0022-z · Cited by 24
Novel epigenetic therapies in hematological malignancies: Current status and beyond
Gallipoli, P., & Huntly, B. J. P. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.07.005 · Cited by 25
Seok, J., Yoon, S., Lee, S., Jung, J. H., & Lee, Y. M. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4649 · Cited by 24
Role of Isocitrate Dehydrogenase 2 on DNA Hydroxymethylation in Human Airway Smooth Muscle Cells
Yeung, B. H. Y., Huang, J., An, S. S., Solway, J., Mitzner, W., & Tang, W. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0323oc · Cited by 25
Anaplastic Astrocytoma: State of the art and future directions
Caccese, M., Padovan, M., D’Avella, D., Chioffi, F., Gardiman, M. P., Berti, F., Busato, F., Bellu, L., Bergo, E., Zoccarato, M., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103062 · Cited by 26
Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes and in Acute Myeloid Leukemias
Testa, U., Castelli, G., & Pelosi, E. (2020) · Cancers · doi:10.3390/cancers12092427 · Cited by 26
Persico, P., Lorenzi, E., Losurdo, A., Dipasquale, A., Muzio, A. D., Navarria, P., Pessina, F., Politi, L. S., Lombardi, G., Santoro, A., et al. (2022) · Cancers · doi:10.3390/cancers14051125 · Cited by 25
Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells
Gruber, E., So, J., Lewis, A. C., Franich, R. L., Cole, R., Martelotto, L. G., Rogers, A. J., Vidacs, E., Fraser, P., Stanley, K. L., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111182 · Cited by 28
Lee, K.-H., Kim, S., Kim, E. E., Shim, Y., Won, J., Park, C., Choi, S. H., Yun, H., Lee, H., & Park, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-32153-y · Cited by 25
Wang, K., Gong, Z., Chen, Y., Zhang, M., Wang, S., Yao, S., Liu, Z., Huang, Z., & Fei, B. (2023) · Clinical Epigenetics · doi:10.1186/s13148-023-01579-6 · Cited by 28
Song, X., Tiek, D. M., Miki, S., Huang, T., Lu, M., Goenka, A., Iglesia, R. P., Yu, X., Wu, R., Walker, M. N., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci173789 · Cited by 25
Medina-Cleghorn, D., & Nomura, D. K. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.07.007 · Cited by 25
Estévez-García, I. O., Cordoba-Gonzalez, V., Lara‐Padilla, E., Fuentes-Toledo, A., Falfán‐Valencia, R., Campos‐Rodríguez, R., & Abarca‐Rojano, E. (2014) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-014-0328-1 · Cited by 25
Xu, H. N., Nioka, S., & Li, L. Z. (2013) · Biomarker Research · doi:10.1186/2050-7771-1-6 · Cited by 25
Ahmed, K. A., & Chinnaiyan, P. (2014) · Metabolites · doi:10.3390/metabo4030740 · Cited by 26
Pharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid Leukemia
Lu, R., & Wang, G. G. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00241 · Cited by 26
Cofactors As Metabolic Sensors Driving Cell Adaptation in Physiology and Disease
Rabhi, N., Hannou, S. A., Froguel, P., & Annicotte, J. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00304 · Cited by 27
Cancer metabolism in a snapshot: MRS(I)
Julià‐Sapé, M., Candiota, A. P., & Arús, C. (2019) · NMR in Biomedicine · doi:10.1002/nbm.4054 · Cited by 25
Wu, B., Pan, X., Chen, X., Chen, M., Shi, K., Xu, J., Zheng, J., Niu, T., Chen, C., Shuai, X., et al. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0040-2 · Cited by 25
Garrett-Bakelman, F. E., & Melnick, A. M. (2016) · Epigenomics · doi:10.2217/epi-2016-0008 · Cited by 25
Self-citationTripathi, S., Nathan, C. L., Tate, M. C., Horbinski, C., Templer, J. W., Rosenow, J. M., Sita, T. L., James, C. D., Deneen, B., Miller, S. D., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.174753 · Cited by 27
D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation
Pianka, S. T., Li, T., Prins, T. J., Eldred, B. S. C., Kevan, B. M., Liang, H., Rinonos, S. Z., Kornblum, H. I., Nathanson, D. A., Pellegrini, M. A., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0271 · Cited by 24
Extracellular glutamate and IDH1R132H inhibitor promote glioma growth by boosting redox potential
Tiburcio, P. D. B., Gillespie, D. L., Jensen, R. L., & Huang, E. L. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03359-w · Cited by 25
Mehrjardi, N. Z., Hänggi, D., & Kahlert, U. D. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03196-0 · Cited by 23
Illuminating the cross-talk between tumor metabolism and immunity in IDH-mutated cancers
Leca, J., Fortin, J., & Mak, T. W. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.11.013 · Cited by 23
Crake, R., Burgess, E. R., Royds, J. A., Phillips, E., Vissers, M. C. M., & Dachs, G. U. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.619300 · Cited by 24
Wang, H., Wang, X., Xu, L., Zhang, J., & Cao, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-91382-1 · Cited by 24
Calvo-Vidal, M. N., & Cerchietti, L. C. A. (2013) · Current Opinion in Hematology · doi:10.1097/moh.0b013e3283623d16 · Cited by 24
Fiehn, O., Showalter, M. R., Tooley, C. E. S., & Reproducibility Project: Cancer Biology (2016) · eLife · doi:10.7554/elife.12626 · Cited by 24
Prakash, C., Fan, B., Altaf, S. A., Agresta, S., Liu, H., & Yang, H. Q. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03793-7 · Cited by 24
Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1
Alghamri, M. S., Thalla, R., Avvari, R., Dabaja, A. A., Taher, A. W., Zhao, L., Ulintz, P., Castro, M. G., & Lowenstein, P. R. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa042 · Cited by 25
Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma
Radoul, M., Hong, D., Gillespie, A. M., Najac, C., Viswanath, P., Pieper, R. O., Costello, J., Luchman, H. A., & Ronen, S. M. (2021) · Metabolites · doi:10.3390/metabo11020109 · Cited by 24
Metabolic adaptations in cancer progression
Peng‐Winkler, Y., & Fendt, S. (2025) · Physiological Reviews · doi:10.1152/physrev.00037.2024 · Cited by 25
Isocitrate dehydrogenase 1: what it means to the neurosurgeon
Hodges, T. R., Choi, B. D., Bigner, D. D., Yan, H., & Sampson, J. H. (2013) · Journal of neurosurgery · doi:10.3171/2013.3.jns122282 · Cited by 23
Isocitrate dehydrogenase mutations in chondrosarcoma
Azzi, G., Velez, M., & Mathias-Machado, M. C. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000092 · Cited by 23
Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses
Cheng, W., Ren, X., Zhang, C., Cai, J., Han, S., & Wu, A. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0150-6 · Cited by 24
Guo, X., Zhang, M., Cao, M., Zhang, W., Kang, Z., Xu, P., Ma, C., & Gao, C. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003897 · Cited by 22
IDH Mutations in AML Patients; A higher Association with Intermediate Risk Cytogenetics
Elnahass, Y., Badawy, R. H., Elrefaey, F. A., Nooh, H. A., Ibrahiem, D., Nader, H., Mahmoud, H. K., & El-Metnawy, W. (2020) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2020.21.3.721 · Cited by 23
Connections between metabolism and epigenetic modifications in cancer
Wang, G., & Han, J. J. (2021) · Medical Review · doi:10.1515/mr-2021-0015 · Cited by 27
Yao, K., Liu, H., Yu, S., Zhu, H., & Pan, J. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215603 · Cited by 25
Dermawan, J. K. T. K., Nafa, K., Mohanty, A. S., Xu, Y., Rijo, I., Casanova, J., Villafania, L. B., Benhamida, J. K., Kelly, C. M., Tap, W. D., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0397 · Cited by 23
Karagiannis, D., Wu, W., Li, A. M., Hayashi, M., Chen, X., Yip, M., Mangipudy, V. S., Xu, X., Rivera, F. J. S., Soto‐Feliciano, Y. M., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113629 · Cited by 26
RIPK3 deficiency blocks R-2-hydroxyglutarate–induced necroptosis in IDH-mutated AML cells
Zhu, S., Luo, Y., Li, K., Mei, C., Wang, Y., Jiang, L., Wang, W., Zhang, Q., Yang, W., Lang, W., et al. (2024) · Science Advances · doi:10.1126/sciadv.adi1782 · Cited by 24
The role of mutation of metabolism-related genes in genomic hypermethylation
Waterfall, J. J., Killian, J. K., & Meltzer, P. S. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.08.003 · Cited by 23
IDHmutations: new genetic signatures in cholangiocarcinoma and therapeutic implications
Borger, D. R., & Zhu, A. X. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.32 · Cited by 23
Expanding the Reach of Cancer Metabolomics
Metallo, C. M. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-12-0433 · Cited by 23
Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer
Brody, J. R., Yabar, C. S., Zarei, M., Bender, J., Matrisian, L. M., Rahib, L., Heartwell, C., Mason, K., Yeo, C. J., Peiper, S. C., et al. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1210743 · Cited by 23
Impact of DNA methylation programming on normal and pre-leukemic hematopoiesis
Langstein, J., Milsom, M. D., & Lipka, D. B. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.09.008 · Cited by 25
Molecular Genetics of Secondary Glioblastoma
Mansouri, A., Karamchandani, J., & Das, S. (2017) · Codon Publications eBooks · doi:10.15586/codon.glioblastoma.2017.ch2 · Cited by 23
Dodo, M., Kitamura, H., Shima, H., Saigusa, D., Wati, S. M., Ota, N., Katsuoka, F., Chiba, H., Okae, H., Arima, T., et al. (2018) · The Journal of Biochemistry · doi:10.1093/jb/mvy108 · Cited by 24
Epigenetic regulation by endogenous metabolite pharmacology
Kulkarni, R. A., Montgomery, D. C., & Meier, J. L. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.02.002 · Cited by 24
In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site
Chaturvedi, A., Goparaju, R., Gupta, C., Weder, J., Klünemann, T., Cruz, M. M. A., Kloos, A., Görlich, K., Schottmann, R., Othman, B., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0582-x · Cited by 25
Clinical developments in epigenetic-directed therapies in acute myeloid leukemia
Pan, D., Rampal, R. K., & Mascarenhas, J. O. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001245 · Cited by 23
Metformin targets histone acetylation in cancer-prone epithelial cells
Cuyàs, E., Fernández‐Arroyo, S., Joven, J., & Menéndez, J. A. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1249547 · Cited by 23
Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending Questions
Wouters, B. J. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000583 · Cited by 22
Getting the right combination to break the epigenetic code
Tolu, S. S., Viny, A. D., Amengual, J. E., Pro, B., & Bates, S. E. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00972-1 · Cited by 24
Gao, M., Zhu, H., Li, F., Li, Y., Bao, X., Fu, H., Quan, H., Wang, L., & Lou, L. (2019) · Cancer Science · doi:10.1111/cas.14152 · Cited by 21
Shen, X., Wu, S., Zhang, J., Li, M., Xu, F., Wang, A., Yang, L., & Zhu, G. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11250 · Cited by 22
Nuclear FABP7 regulates cell proliferation of wild‐type IDH1 glioma through caveolae formation
Kagawa, Y., Umaru, B. A., Kanamori, M., Zama, R., Shil, S. K., Miyazaki, H., Kobayashi, S., Wannakul, T., Yang, S., Tominaga, T., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.13130 · Cited by 23
Kunadt, D., Stasik, S., Metzeler, K. H., Röllig, C., Schliemann, C., Greif, P. A., Spiekermann, K., Rothenberg‐Thurley, M., Krug, U. O., Braess, J., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01339-8 · Cited by 22
Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
Lyu, J., Liu, Y., Gong, L., Chen, M., Madanat, Y. F., Zhang, Y., Cai, F., Gu, Z., Cao, H., Kaphle, P., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1661 · Cited by 23
He, Q., Chen, J., Xie, Z., & Chen, Z. (2022) · Cancers · doi:10.3390/cancers14235779 · Cited by 24
Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma
Pang, Y., Lu, T., Xu-Monette, Z. Y., & Young, K. H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065493 · Cited by 28
HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant glioma
Garrett, M. C., Albano, R., Carnwath, T., Elahi, L. S., Behrmann, C. A., Pemberton, M., Woo, D., O'Brien, E. J., VanCauwenbergh, B., Perentesis, J. P., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-33889-3 · Cited by 27
Soto‐Pantoja, D. R., Sipes, J. M., Martin‐Manso, G., Westwood, B. M., Morris, N., Ghosh, A., Emenaker, N. J., & Roberts, D. D. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.37 · Cited by 22
RNA-Guided CRISPR-Cas9 System-Mediated Engineering of Acute Myeloid Leukemia Mutations
Brabetz, O., Alla, V., Angenendt, L., Schliemann, C., Berdel, W. E., Arteaga, M. F., & Mikesch, J. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2016.12.012 · Cited by 22
Metadata
- Authors
- Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., Wellen, K. E., O’Rourke, D. M., Berger, S. L., Chan, T. A., Levine, R. L., Mellinghoff, I. K., & Thompson, C. B.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- University of Pennsylvania (US)
- Weill Cornell Medicine (US)
- Corresponding author
- Thompson, Craig B.
- ORCID
- Venue
- Nature
- Published
- 2012-02-15
- Volume
- 483
- Issue
- 7390
- Pages
- 474-478
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3478770
- OpenAlex
- W2154313451
- Cited by
- 1,985
- References
- 30
- Citations by year
- 2026: 81 · 2025: 93 · 2024: 106 · 2023: 125 · 2022: 122 · 2021: 180 · 2020: 170 · 2019: 153 · 2018: 146 · 2017: 163 · 2016: 151 · 2015: 123 · 2014: 138 · 2013: 136 · 2012: 91
- FWCI
- 74.69
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- University of Pennsylvania
- National Cancer Institute (R01CA078831, R01CA105463, U54CA143798)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- 2-hydroxyglutarate, histone demethylation, histone methylation, glioma, oncometabolites, DNA hypermethylation, hypoxia-inducible factor, adipogenesis, neural progenitor cells
- MeSH terms
- Animals, Astrocytes, Cell Differentiation, Enzyme Induction, Gene Expression Regulation, Glioma, Glutarates, Histones, Humans, Isocitrate Dehydrogenase, Methylation, Mutation, Promoter Regions, Genetic, Adipocytes, Cell Lineage, DNA Methylation, 3T3-L1 Cells, Cell Line, Tumor, Mice, Jumonji Domain-Containing Histone Demethylases, HEK293 Cells, Neural Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
